

# Lysiane Marthey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9325972/publications.pdf>

Version: 2024-02-01

17  
papers

1,998  
citations

623734

14  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

3352  
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810.	10.7	719
2	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 395-401.	1.3	274
3	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	12.1	179
4	Olmesartan-associated enteropathy: results of a national survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1103-1109.	3.7	166
5	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015, 113, 989-995.	6.4	151
6	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. <i>Annals of Surgical Oncology</i> , 2015, 22, 295-301.	1.5	145
7	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE). <i>TJ ETQq1 1 0.784314 rgBT /Ove</i>	0.9	104
8	Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 852-859.	6.4	77
9	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	4.4	47
10	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	2.8	41
11	Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. <i>European Journal of Cancer</i> , 2019, 119, 35-43.	2.8	24
12	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	6.4	22
13	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021, 124, 1941-1948.	6.4	20
14	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , 2016, 48, 441-445.	0.9	17
15	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101603.	1.5	12
16	Letter: sprue-like enteropathy associated with angiotensin <sc>II</sc> receptor blockers other than olmesartan authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 473-474.	3.7	0
17	P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI). <i>Journal of Crohn's and Colitis</i> , 2018, 12, S289-S290.	1.3	0